Abhishek Deshmukh, MD
Cardiovascular Disease · Rochester, MNNPI 1538359906
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by GE HealthCare at 53.1% of the total. 2025 is the largest year on record at $29,081, more than ten times the $1,627 reported in 2022.
Across 37 payments — averaging $1325.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GE HealthCare$26K
- Biosense Webster, Inc.$22K
- Medtronic$1K
- Abbott$216
Across 112 payments — averaging $3797.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$406K
- Cala Health, Inc.$19K
What the payments were for
- Consulting fees$20,78742%
- Speaking & faculty fees$19,05039%
- Travel & lodging$8,54917%
- Food & beverage$6671%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GE HealthCare | 18 | $26,038 |
| Biosense Webster, Inc. | 16 | $21,599 |
| Medtronic | 1 | $1,200 |
| Abbott | 2 | $216 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,053 in reported general payments places this provider in the 85th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 52 | $69,831 |
| XareltoRivaroxaban | 30 | $25,179 |
| Dofetilide | 21 | $4,782 |
| Metoprolol Succinate | 55 | $920 |
| Amiodarone Hcl | 45 | $898 |
| SotalolSotalol Hcl | 17 | $411 |
| Atorvastatin Calcium | 11 | $393 |
| Losartan Potassium | 16 | $293 |
| Lisinopril | 17 | $65 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Rochester
- Srijoy MahapatraRochester$1.2M
- Charanjit RihalRochester$478K
- Amir LermanRochester$465K
- Martha GroganRochester$330K
- Virend SomersRochester$262K
- Francisco Lopez-JimenezRochester$167K
- Ammar KilluRochester$139K
- Allan JaffeRochester$111K
- Robert McBaneRochester$110K
- Michael McGoonRochester$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.